Insider Trading Alert - ASYS, LCI And USPH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 1, 2014, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $311.47 to $11,658,664.23.

Highlighted Stocks Traded by Insiders:

Amtech Systems (ASYS) - FREE Research Report

Schreyer Leslie J, who is 10% Owner at Amtech Systems, bought 100,000 shares at $8.98 on Dec. 1, 2014. Following this transaction, the 10% Owner owned 891,750 shares meaning that the stake was boosted by 12.63% with the 100,000-share transaction.

The shares most recently traded at $8.40, down $0.58, or 6.96% since the insider transaction. Historical insider transactions for Amtech Systems go as follows:

  • 4-Week # shares bought: 15,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares bought: 17,500
  • 24-Week # shares sold: 2,000

The average volume for Amtech Systems has been 37,700 shares per day over the past 30 days. Amtech Systems has a market cap of $89.4 million and is part of the technology sector and electronics industry. Shares are up 30.46% year-to-date as of the close of trading on Friday.

Amtech Systems, Inc. designs, assembles, sells, and installs capital equipment and related consumables used in the manufacture of wafers, primarily for the solar and semiconductor industries worldwide. Currently, there are 3 analysts who rate Amtech Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASYS - FREE

TheStreet Quant Ratings rates Amtech Systems as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. Get the full Amtech Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lannett (LCI) - FREE Research Report

Farber David, who is 10% Owner at Lannett, sold 7,500 shares at $50.00 on Dec. 1, 2014. Following this transaction, the 10% Owner owned 35,870 shares meaning that the stake was reduced by 17.29% with the 7,500-share transaction.

The shares most recently traded at $46.34, down $3.66, or 7.9% since the insider transaction. Historical insider transactions for Lannett go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 47,500
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 75,000

The average volume for Lannett has been 808,100 shares per day over the past 30 days. Lannett has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 48.43% year-to-date as of the close of trading on Friday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 17.9. Currently, there are 3 analysts who rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Lannett Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

US Physical Therapy (USPH) - FREE Research Report

Reading Christopher J, who is Chief Executive Officer at US Physical Therapy, sold 9,759 shares at $39.29 on Dec. 1, 2014. Following this transaction, the Chief Executive Officer owned 104,157 shares meaning that the stake was reduced by 8.57% with the 9,759-share transaction.

The shares most recently traded at $39.04, down $0.25, or 0.64% since the insider transaction. Historical insider transactions for US Physical Therapy go as follows:

  • 4-Week # shares bought: 250
  • 4-Week # shares sold: 21,243
  • 12-Week # shares bought: 250
  • 12-Week # shares sold: 21,243
  • 24-Week # shares bought: 250
  • 24-Week # shares sold: 32,243

The average volume for US Physical Therapy has been 45,600 shares per day over the past 30 days. US Physical Therapy has a market cap of $475.8 million and is part of the health care sector and health services industry. Shares are up 10.24% year-to-date as of the close of trading on Friday.

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics in the United States. The stock currently has a dividend yield of 1.24%. The company has a P/E ratio of 23.8. Currently, there are 2 analysts who rate US Physical Therapy a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USPH - FREE

TheStreet Quant Ratings rates US Physical Therapy as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full US Physical Therapy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%